Researchers develop novel nanolitre screening technique
Determines protein stability and ligand‐binding affinity
This technique, pioneered by researchers from the UCL Department of Biochemical Engineering and the London Centre for Nanotechnology, in collaboration with Cambridge and Sussex Universities, is applicable to any free solution protein:drug interaction.
The technique applies microfluidics, using just nanolitres of sample – coupling protein stability and drug affinity analysis to microfluidic devices for sample preparation.
In a paper published in Protein Science journal, the researchers established a new nanolitre scale technique in micro-capillaries to measure intrinsic protein fluorescence and obtain accurate protein denaturation curves at equilibrium.
Free energies of protein unfolding were determined by this method for the first time and used to determine the affinity of the immunosuppressant rapamycin to the cellular immunophilin FKBP12 protein. The technique was also used to measure the interaction energy between rapamycin and the Phe99 residue of FKBP-12 from a double mutant cycle analysis. The method used combinations of two different protein mutations to study the molecular interactions within a given protein.
Until now, the modus operandi for protein analysis often meant either too much of the precious biological or compound materials was consumed in large sample volumes, or that chemical labelling with fluorescent tags was required to achieve measurements at submicrolitre volumes.
Dr David Sarphie, BNC’s chief executive, said: ‘This new method has vast implications and uses high throughput, low-cost platforms for drug discovery, protein engineering and protein formulation applications in the pharmaceutical industry.
‘Moreover, this technology marks a further development in the implementation of our corporate strategy to forge industry collaborations with leading academic and scientific organisations that possess the know-how to assess novel drug targets.’
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
From bespoke to scalable: closing the manufacturing gap in advanced therapeutics
Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing
Piramal Pharma Solutions announces partnership with Botanix to support drug substance development
Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra